BioNTech SE today announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy ("iNeST") candidate autogene cevumeran (BNT122, RO7198457) in patients with resected pancreatic ductal adenocarcinoma ("PDAC"). The data show that in 8 out of 16 patients, autogene cevumeran elicited an immune response up to three years post-administration measured by activated T cells. The persistence of T cells was associated with a longer median recurrence-free survival in cancer vaccine responders.
English (US) ·